CHRONIC KIDNEY DISEASE IN CHILDREN

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 国家糖尿病、消化和肾脏疾病研究所（NIDDK）的肾脏、泌尿和血液疾病部门（DKUHD）与国家神经疾病和中风研究所（NINDS）、国家儿童健康和人类发育研究所（NICHD）和国家心脏病研究所合作，肺和血液研究所（NHLBI）资助了一项合作协议，对慢性肾脏病（CKD）儿童进行前瞻性流行病学研究。本研究的主要目的是确定肾功能下降的风险因素，并确定肾功能进行性下降如何影响神经认知功能和行为;心血管疾病的风险因素;以及生长衰竭及其相关发病率。 具体目标是 确定儿童CKD进展的新型和传统肾脏疾病风险因素（例如GFR下降）， 描述肾功能下降对神经发育、认知能力和行为的影响， 确定进行性CKD中传统和新型心血管疾病风险因素的患病率和演变， 检查GFR下降对生长和生长失败治疗的影响，并评估生长失败对CKD儿童发病率的影响。 本研究将招募1至16岁（17岁之前）的轻度至中度CKD儿童。 大约540名儿童将在全国57个不同的地点参加这项研究。 约20名儿童将被要求在辛辛那提儿童医院医疗中心参加这项研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Division of Kidney, Urologic, and Hematologic Diseases (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Child Health and Human Development (NICHD) and the National Heart, Lung and Blood Institute (NHLBI) funded a cooperative agreement to conduct a prospective epidemiological study of children with chronic kidney disease (CKD). The primary goals of this study are to determine the risk factors for decline in kidney function and to define how a progressive decline in kidney function impacts neurocognitive function and behavior; the risk factors for cardiovascular disease; and growth failure and its associated morbidity. The specific aims are Identify novel and traditional renal disease risk factors for the progression of CKD (e.g. decline of GFR) in children, Characterize the impact of a decline in kidney function on neurodevelopment, cognitive abilities, and behavior, Identify the prevalence and evolution of traditional and novel cardiovascular disease risk factors in progressive CKD, and Examine the effects of declining GFR on growth and the treatment of growth failure, and to assess the consequences of growth failure on morbidity in children with CKD. Children 1 to 16 years old (before 17th birthday) with mild to moderate CKD will be recruited for this study. About 540 children will be in this study at 57 different sites around the country. About 20 children will be asked to be in this study at Cincinnati Children's Hospital Medical Center.